Cancer Pain Management: WHO Analgesic Ladder, Opioid Rotation, Breakthrough Dosing

Cancer Pain Management: WHO Analgesic Ladder, Opioid Rotation, Breakthrough Dosing

A practical guide for clinicians managing cancer-related pain.

What Is This?

This guide explains the WHO Analgesic Ladder, opioid rotation, and breakthrough dosing—three cornerstones of cancer pain management. Clinicians use these frameworks to: - Titrate analgesics systematically based on pain severity. - Switch opioids when tolerance or side effects develop. - Prevent and treat sudden pain flares (breakthrough pain) without overdosing.

Cancer pain is dynamic—patients may experience nociceptive (tissue damage), neuropathic (nerve injury), or mixed pain. These tools help clinicians match treatment to pain type and intensity while minimizing harm.

Why It Matters

• 80% of advanced cancer patients experience moderate-to-severe pain, yet 30% receive inadequate analgesia (WHO, 2020).
• Opioid misuse (e.g., over-sedation, respiratory depression) is a leading cause of preventable harm in palliative care.
• Breakthrough pain occurs in 50–90% of cancer patients, often peaking in 3–5 minutes and lasting 30–60 minutes. Poor management leads to uncontrolled suffering and hospital readmissions.
• Opioid rotation can restore analgesia in 50–70% of patients with tolerance or toxicity (e.g., hyperalgesia, delirium).

Bottom line: These tools save lives, reduce suffering, and cut healthcare costs by preventing uncontrolled pain and opioid-related complications.

Core Concepts

1. WHO Analgesic Ladder: A Stepwise Approach to Pain Control

A 3-step framework for escalating analgesics based on pain severity (1–10 scale).

Adjuvants (co-analgesics): - Neuropathic pain: Gabapentin, pregabalin, TCAs (amitriptyline), SNRIs (duloxetine). - Bone pain: Bisphosphonates (zoledronate), denosumab, NSAIDs. - Inflammation: Corticosteroids (dexamethasone).

When to escalate? - If pain is uncontrolled (score ?4) for >24 hours despite max-tolerated dose. - If side effects (e.g., nausea, constipation) limit dose increases.

2. Opioid Rotation: Switching Opioids to Improve Efficacy or Reduce Toxicity

Why rotate? - Tolerance: Loss of analgesic effect over time. - Toxicity: Unmanageable side effects (e.g., myoclonus, delirium, hyperalgesia). - Pharmacogenetics: Poor metabolizers (e.g., CYP2D6 deficiency-codeine inefficacy). - Route changes: Oral-transdermal (e.g., fentanyl patch) if swallowing is difficult.

How to rotate?
1. Calculate equianalgesic dose (see table below).
2. Reduce new opioid dose by 25–50% (accounts for incomplete cross-tolerance).
3. Titrate to effect while monitoring for side effects.

Example Rotation: - Patient on morphine 60mg PO q4h (total 360mg/day) with uncontrolled pain + myoclonus. - Equianalgesic dose of hydromorphone: 360mg morphine ÷ 5 = 72mg hydromorphone/day. - Reduce by 30%: 72mg × 0.7 = 50mg hydromorphone/day (e.g., 8mg q4h). - Monitor for 24–48h, adjust as needed.

Pitfalls: - Methadone rotation requires expert consultation (risk of accumulation and QTc prolongation). - Fentanyl patches are not for opioid-naïve patients (risk of respiratory depression).

3. Breakthrough Dosing: Managing Sudden Pain Flares

Definition: Transient exacerbations of pain despite stable background analgesia.

Key Principles: - Dose: 10–20% of total daily opioid dose (e.g., if on 100mg morphine/day, breakthrough dose = 10–20mg). - Route: Immediate-release (IR) oral (e.g., morphine IR, oxycodone IR) or IV/SC if oral not feasible. - Frequency: Every 1–2 hours as needed (max 4–6 doses/day). - Reassess: If using >3 breakthrough doses/day, increase background dose by 25–50%.

Example: - Patient on morphine SR 60mg q12h (total 120mg/day). - Breakthrough dose: 120mg × 10% = 12mg morphine IR q1h PRN. - If using 4 doses/day, increase background dose to 150mg/day (e.g., 75mg q12h).

Special Cases: - Incident pain (e.g., dressing changes, movement): Pre-dose 30–60 min before activity. - Neuropathic breakthrough pain: Consider gabapentin or ketamine (consult pain specialist). - End-of-dose failure: Shorten dosing interval (e.g., q8h-q6h) or switch to longer-acting opioid.

How It Works (Clinical Workflow)

1. Assess Pain
2. Type: Nociceptive (aching, throbbing) vs. neuropathic (burning, shooting).
3. Severity: Numeric Rating Scale (NRS) 0–10.

4. Temporal pattern: Constant vs. breakthrough vs. incident.

5. Start on WHO Ladder

6. Step 1 (mild pain): Paracetamol 1g q6h + adjuvant (e.g., gabapentin for neuropathic pain).
7. Step 2 (moderate pain): Add weak opioid (e.g., tramadol 50mg q6h) or low-dose strong opioid (e.g., morphine 5mg q4h).

8. Step 3 (severe pain): Strong opioid (e.g., morphine 10mg q4h) + adjuvant.

9. Titrate Background Dose

10. Increase by 25–50% every 24h until pain controlled or side effects limit dose.

11. Example: Morphine 10mg q4h-15mg q4h if pain score ?4 after 24h.

12. Prescribe Breakthrough Dose

13. 10–20% of total daily opioid dose, q1h PRN.

14. Reassess every 24h: If using >3 doses/day, increase background dose.

15. Rotate Opioids if Needed

16. Indications: Tolerance, toxicity, or poor efficacy.

17. Steps:

    1. Calculate equianalgesic dose.
    2. Reduce by 25–50%.
    3. Titrate to effect.

18. Monitor & Adjust

19. Efficacy: Pain score, functional status.
20. Toxicity: Sedation, constipation, nausea, respiratory rate.
21. Tools:
    • Opioid Risk Tool (ORT) for addiction risk.
    • Edmonton Symptom Assessment System (ESAS) for symptom burden.

Hands-On / Getting Started

Prerequisites

• Knowledge:
• Basic pharmacology of opioids (?-receptor agonists, metabolism, side effects).
• Pain assessment tools (NRS, PQRST mnemonic).
• Skills:
• Calculating equianalgesic doses.
• Recognizing opioid toxicity (e.g., pinpoint pupils, respiratory depression).
• Resources:
• Opioid conversion calculator (e.g., MDCalc).
• Palliative care guidelines (e.g., NCCN, ESMO).

Step-by-Step Example: Managing Severe Cancer Pain

Case: 65M with metastatic prostate cancer, NRS 8/10, currently on paracetamol 1g q6h + tramadol 50mg q6h (ineffective).

1. Assess Pain
2. Type: Mixed (nociceptive + neuropathic).
3. Severity: 8/10.

4. Current regimen: Step 2 (weak opioid)-escalate to Step 3.

5. Start Strong Opioid

6. Morphine 5mg PO q4h (total 30mg/day).

7. Breakthrough dose: 30mg × 10% = 3mg morphine IR q1h PRN.

8. Titrate Over 48h

9. Day 1: Pain 6/10-increase to 7.5mg q4h (total 45mg/day).

10. Day 2: Pain 5/10, using 2 breakthrough doses-increase to 10mg q4h (total 60mg/day).

11. Add Adjuvant for Neuropathic Pain

12. Gabapentin 300mg TID (titrate to 1200mg/day over 1 week).

13. Reassess at 72h

14. Pain 3/10, no breakthrough doses-maintain current regimen.

15. Side effects: Constipation-senna 15mg daily + docusate 100mg BID.

16. If Pain Worsens (e.g., NRS 7/10)

17. Option 1: Increase morphine to 15mg q4h (total 90mg/day).
18. Option 2: Rotate to hydromorphone 3mg q4h (equianalgesic dose: 90mg morphine ÷ 5 = 18mg hydromorphone-reduce by 30% = 12.6mg/day-3mg q4h).

Expected Outcome: - Pain controlled (NRS ?3) within 48–72h. - Breakthrough doses <3/day. - Side effects managed (e.g., constipation, nausea).

Common Pitfalls & Mistakes

Best Practices

1. Opioid Prescribing

• Start low, go slow: Titrate every 24h (faster in severe pain).
• Use long-acting + short-acting: SR (sustained-release) for background, IR (immediate-release) for breakthrough.
• Avoid meperidine (pethidine): Toxic metabolite (normeperidine)-seizures.
• Monitor for opioid-induced hyperalgesia (OIH): If pain worsens with dose increases, consider opioid rotation or ketamine.

2. Breakthrough Pain

• Pre-dose for predictable pain (e.g., wound dressing changes).
• Use same opioid for background and breakthrough (e.g., morphine SR + morphine IR).
• If using >4 breakthrough doses/day, increase background dose by 25–50%.

3. Opioid Rotation

• Reduce new opioid dose by 25–50% (accounts for incomplete cross-tolerance).
• Avoid methadone in primary care (complex pharmacokinetics, QTc risk).
• Fentanyl patches: Never cut patches (dose dumping risk). Apply to non-hairy skin, change every 72h.

4. Side Effect Management

Tools & Frameworks

Real-World Use Cases